BC is a heterogeneous disease and consists of three major tumor subtypes, which depend on the availability of molecular biomarkers for HER2, estrogen receptor (ER), or progesterone receptor (PR) (Mehraj et al., 2022). This evidence concerns the gene ERBB2 and breast cancer.